Reported 1 day ago
H.C. Wainwright has reaffirmed a Buy rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR), setting a price target of $80. This decision follows a significant $200 million deal with Novartis, which may yield up to $2 billion, highlighting Arrowhead’s approach to treating CNS diseases. The deal not only provides crucial funding but also avoids share dilution. Analyst Patrick Trucchio emphasized Arrowhead's appeal due to its quarterly dosing and positive data from related drug studies helping treat severe hypertriglyceridemia.
Source: YAHOO